This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nintedanib for progressive fibrosing interstitial lung disease

< Back

Nintedanib for progressive fibrosing interstitial lung disease


Respiratory Disease and Thoracic Surgery

January 2019

Nintedanib is an oral medicinal product under clinical development for patients with progressive fibrosing interstitial lung disease (PF-ILD). ILDs belong to a group of over 200 rare conditions that affect the tissue and space around the air sacs of the lungs, where tissue becomes thickened, stiff and scarred over a period of time. PF-ILDs are a specific sub-type where there is a progressive scarring (fibrosis) of the lung tissue that results in worsening respiratory symptoms, lung function decline, limited response to immunomodulatory therapies, organ failure, decreased quality of life and, potentially, early death.
Nintedanib is already licensed for treating idiopathic pulmonary fibrosis which is a subtype of ILDs. Nintedanib acts by blocking specific enzymes and pathways that lead to the development of blood vessels within lung cells involved in the scarring process. This inhibits further growth of the scarring tissues resulting in slowing of the disease progression. This action has been shown to be similar in patients with idiopathic pulmonary fibrosis. If licensed, nintedanib may provide the first novel therapy for PF-ILD where limited treatment options currently exist.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts